{"preliminary_commentary":{"by_channel":{"x_thread":12},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04234568\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["triapine","lutetium-177 dotatate"]],"indication":"well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors","name":"ETCTN 10388","nct_id":"NCT04234568","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=etctn-10388-nct04234568. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients receive lutetium Lu 177 dotatate IV for 30 to 40 minutes on day 1 of each cycle and triapine PO on days 1 throughout 14 of each cycle. Cycles repeat every 56 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan or MRI scan throughout the trial. Patients undergo blood specimen collection on study.","label":"Treatment (lutetium Lu 177 dotatate, triapine)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-03-13","type":"ESTIMATED"},"conditions":["Metastatic Digestive System Neuroendocrine Neoplasm","Metastatic Neuroendocrine Tumor"],"enrollment":{"count":31,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Biospecimen Collection","otherNames":["Biological Sample Collection","Biospecimen Collected","Sample Collection","Specimen Collection"],"type":"PROCEDURE"},{"name":"Computed Tomography","otherNames":["CAT","CAT Scan","Computed Axial Tomography","Computerized Axial Tomography","Computerized axial tomography (procedure)","Computerized Tomography","Computerized Tomography (CT) scan","CT","CT Scan","Diagnostic CAT Scan","Diagnostic CAT Scan Service Type","tomography"],"type":"PROCEDURE"},{"name":"Lutetium Lu 177 Dotatate","otherNames":["177 Lu-DOTA-TATE","177 Lu-DOTA-Tyr3-Octreotate","177Lu-DOTA0-Tyr3-Octreotate","Lutathera","Lutetium (177Lu) Oxodotreotide","Lutetium Lu 177 DOTA(0)-Tyr(3)-Octreotate","Lutetium Lu 177-DOTA-Tyr3-Octreotate","lutetium Lu 177-DOTATATE","Lutetium Oxodotreotide Lu-177"],"type":"DRUG"},{"name":"Magnetic Resonance Imaging","otherNames":["Magnetic Resonance","Magnetic Resonance Imaging (MRI)","Magnetic resonance imaging (procedure)","Magnetic Resonance Imaging Scan","Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance","MR","MR Imaging","MRI","MRI Scan","MRIs","NMR Imaging","NMRI","Nuclear Magnetic Resonance Imaging","sMRI","Structural MRI"],"type":"PROCEDURE"},{"name":"Triapine","otherNames":["3-aminopyridine-2-carboxaldehyde thiosemicarbazone","3-AP","3-Apct","OCX-0191","OCX-191","OCX191","PAN-811"],"type":"DRUG"}],"last_update":"2026-09-18","lead_sponsor":"National Cancer Institute (NCI)","official_title":"A Phase I Trial of Triapine and Lutetium Lu 177 Dotatate in Combination for Well-Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2024-09-17","type":"ACTUAL"},"primary_outcomes":[{"measure":"Maximum Tolerated Dose (MTD) of Triapine and Recommended Phase 2 Dose (RP2D)","timeFrame":"8 weeks (56 days)"},{"measure":"Dose Limiting Toxicity (DLT)","timeFrame":"8 weeks (56 days)"}],"references":[{"citation":"Chauhan A, Weiss HL, Kunos C, Jayswal R, Konda B, Soares HP, Li D, Halfdanarson TR, Mulcahy MF, Jacene HA, Khurana A, Modak R, Yan D, Beumer JH, Christner SM, Wu PI, Das B, Rubinstein LV, Gore SD, Ivy SP, Kohn EC, Carson WE, Anthony LB, Arnold SM. Multi-center Phase 1 study of Triapine in Combination with [177Lu]Lutetium-Dotatate in Patients with Well-Differentiated Neuroendocrine Tumors (ETCTN 10388). Clin Cancer Res. 2026 Jul 28. doi: 10.1158/1078-0432.CCR-26-0686. Online ahead of print.","pmid":"42518206","type":"DERIVED"}],"start_date":{"date":"2020-07-20","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors","url":"https://clinicaltrials.gov/study/NCT04234568"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/etctn-10388-nct04234568"}